David Woodhouse
Chief Executive Officer presso NGM BIOPHARMACEUTICALS, INC.
Profilo
David J.
Woodhouse is currently the Chief Executive Officer & Director at NGM Biopharmaceuticals, Inc. He is also the Chairman at Surrozen, Inc. and a Director at Surrozen Operating, Inc. Previously, he worked as a Managing Director at Goldman Sachs & Co. LLC from 2002 to 2015.
He also served as a Research Assistant at Amgen, Inc. Dr. Woodhouse completed his undergraduate degree at the University of California, Santa Barbara.
He holds an MBA from the Tuck School of Business at Dartmouth and a doctorate from Stanford University School of Medicine.
Posizioni attive di David Woodhouse
Società | Posizione | Inizio |
---|---|---|
NGM BIOPHARMACEUTICALS, INC. | Chief Executive Officer | 01/09/2018 |
SURROZEN, INC. | Chairman | - |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 25/09/2020 |
Precedenti posizioni note di David Woodhouse
Società | Posizione | Fine |
---|---|---|
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Corporate Officer/Principal | 01/01/2015 |
AMGEN INC. | Corporate Officer/Principal | - |
Formazione di David Woodhouse
University of California, Santa Barbara | Undergraduate Degree |
Tuck School of Business at Dartmouth | Masters Business Admin |
Stanford University School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
AMGEN INC. | Health Technology |
NGM BIOPHARMACEUTICALS, INC. | Health Technology |
SURROZEN, INC. | Health Technology |
Aziende private | 2 |
---|---|
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- David Woodhouse